[1] JAHANAFROOZ Z, MOKHTARZADEH A. Pore-forming peptides: a new treatment option for cancer [J]. Curr Med Chem, 2022, 29(23):4078-4096.
[2] MIHAJLOVIC M, LAZARIDIS T. Charge distribution and imperfect amphipathicity affect pore formation by antimicrobial peptides [J]. Biochim Biophys Acta, 2012, 1818(5):1274-1283.
[3] WANG W, KAI D, LU H, et al. The strategies of endosomal escape for intracellular gene delivery [J]. Acta Pharm Sin (药学学报), 2014, 49(8):1111-1116.
[4] PATERSON D J, TASSIERI M, REBOUD J, et al. Lipid topology and electrostatic interactions underpin lytic activity of linear cationic antimicrobial peptides in membranes [J]. Proc Natl Acad Sci USA, 2017, 114(40):e8324-e8332.
[5] VECCHIO A J, RATHNAYAKE S S, STROUD R M. Structural basis for Clostridium perfringens enterotoxin targeting of claudins at tight junctions in mammalian gut [J]. Proc Natl Acad Sci USA, 2021, 118(15):e2024651118. Doi: 10.1073/pnas.2024651118.
[6] QIAO L, YANG H, GAO S, et al. Research progress on self-assembled nanodrug delivery systems [J]. J Mater Chem B, 2022, 10(12):1908-1922.
[7] PI Y, ZHOU J, WANG J, et al. Strategies of overcoming the physiological barriers for tumor-targeted nano-sized drug delivery systems [J]. Curr Pharm Des, 2015, 21(42):6236-6245.
[8] BIRMINGHAM C L, CANADIEN V, KANIUK N A, et al. Listeriolysin O allows Listeria monocytogenes replication in macrophage vacuoles [J]. Nature, 2008, 451(7176):350-354.
[9] PETRIŠIŠ N, KOZOROG M, ADEN S, et al. The molecular mechanisms of listeriolysin O-induced lipid membrane damage [J]. Biochim Biophys Acta Biomembr, 2021, 1863(7):183604. Doi: 10.1016/j.bbamem.2021.183604.
[10] KOZOROG M, SANI M A, LENARI IVKOVIC M, et al. (19)F NMR studies provide insights into lipid membrane interactions of listeriolysin O, a pore forming toxin from Listeria monocytogenes [J]. Sci Rep, 2018, 8(1):6894. Doi: 10.1038/s41598-018-24692-6.
[11] WALLS Z F, GOODELL S, ANDREWS C D, et al. Mutants of listeriolysin O for enhanced liposomal delivery of macromolecules [J]. J Biotechnol, 2013, 164(4):500-502.
[12] WALLS Z F, GONG H, WILSON R J. Liposomal Coencapsulation of Doxorubicin with Listeriolysin O Increases Potency via Subcellular Targeting [J]. Mol Pharm, 2016, 13(3):1185-1190.
[13] PROVODA C J, STIER E M, LEE K D. Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin [J]. J Biol Chem, 2003, 278(37):35102-35108.
[14] KULLBERG M, MANN K, ANCHORDOQUY T J. Targeting Her-2+ breast cancer cells with bleomycin immunoliposomes linked to LLO [J]. Mol Pharm, 2012, 9(7):2000-2008.
[15] MATHEW E, HARDEE G E, BENNETT C F, et al. Cytosolic delivery of antisense oligonucleotides by listeriolysin O-containing liposomes [J]. Gene Ther, 2003, 10(13):1105-1115.
[16] LORENZI G L, LEE K D. Enhanced plasmid DNA delivery using anionic LPDII by listeriolysin O incorporation [J]. J Gene Med, 2005, 7(8):1077-1085.
[17] KULLBERG M, MCCARTHY R, ANCHORDOQUY T J. Gene delivery to Her-2+ breast cancer cells using a two-component delivery system to achieve specificity [J]. Nanomedicine, 2014, 10(6):1253-1262.
[18] KIM N H, PROVODA C, LEE K D. Design and characterization of novel recombinant listeriolysin O-protamine fusion proteins for enhanced gene delivery [J]. Mol Pharm, 2015, 12(2):342-350.
[19] SUN X, PROVODA C, LEE K D. Enhanced in vivo gene expression mediated by listeriolysin O incorporated anionic LPDII:Its utility in cytotoxic T lymphocyte-inducing DNA vaccine [J]. J Controlled Release, 2010, 148(2):219-225.
[20] MANDAL M, LEE K D. Listeriolysin O-liposome-mediated cytosolic delivery of macromolecule antigen in vivo:enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection [J]. Biochim Et Biophysica Acta, 2002, 1563(1-2):7-17.
[21] STIER E M, MANDAL M, LEE K D. Differential cytosolic delivery and presentation of antigen by listeriolysin O-liposomes to macrophages and dendritic cells [J]. Mol Pharm, 2005, 2(1):74-82.
[22] MANDAL M, KAWAMURA K S, WHERRY E J, et al. Cytosolic delivery of viral nucleoprotein by listeriolysin O-liposome induces enhanced specific cytotoxic T lymphocyte response and protective immunity [J]. Mol Pharm, 2004, 1(1):2-8.
[23] ANDREWS C D, HUH M S, PATTON K, et al. Encapsulating immunostimulatory CpG oligonucleotides in listeriolysin O-liposomes promotes a Th1-type response and CTL activity [J]. Mol Pharm, 2012, 9(5):1118-1125.
[24] KULLBERG M, OWENS J L, MANN K. Listeriolysin O enhances cytoplasmic delivery by Her-2 targeting liposomes [J]. J Drug Target, 2010, 18(4):313-320.
[25] PLAZA-GA I, MANZANEDA-GONZALEZ V, KISOVEC M, et al. pH-triggered endosomal escape of pore-forming Listeriolysin O toxin-coated gold nanoparticles [J]. J Nanobiotechnol, 2019, 17(1):108. Doi:10.1186/s12951-019-0543-6.
[26] MANN K, KULLBERG M. Trastuzumab-targeted gene delivery to Her2-overexpressing breast cancer cells [J]. Cancer Gene Ther, 2016, 23(7):221-228.
[27] LEE M T, SUN T L, HUNG W C, et al. Process of inducing pores in membranes by melittin [J]. Proc Natl Acad Sci USA, 2013, 110(35):14243-14248.
[28] VAN DEN BOGAART G, GUZMAN J V, MIKA J T, et al. On the mechanism of pore formation by melittin [J]. J Biol Chem, 2008, 283(49):33854-33857.
[29] OKADA M, ORTIZ E, CORZO G, et al. Pore-forming spider venom peptides show cytotoxicity to hyperpolarized cancer cells expressing K+ channels:A lentiviral vector approach [J]. PLoS One, 2019, 14(4):e0215391. Doi: 10.1371/journal.pone.0215391.
[30] WANG J, LU Z, WIENTJES M G, et al. Delivery of siRNA therapeutics:barriers and carriers [J]. AAPS J, 2010, 12(4):492-503.
[31] HOU K K, PAN H, LANZA G M, et al. Melittin derived peptides for nanoparticle based siRNA transfection [J]. Biomaterials, 2013, 34(12):3110-3119.
[32] HOU K K, PAN H, RATNER L, et al. Mechanisms of nanoparticle-mediated siRNA transfection by melittin-derived peptides [J]. ACS Nano, 2013, 7(10):8605-8615.
[33] KEIL T W M, BALDASSI D, MERKEL O M. T-cell targeted pulmonary siRNA delivery for the treatment of asthma [J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2020, 12(5):e1634. Doi: 10.1002/wnan.1634.
[34] KIM M G, SHON Y, KIM J, et al. Selective Activation of Anticancer Chemotherapy by Cancer-Associated Fibroblasts in the Tumor Microenvironment [J]. J Natl Cancer Inst, 2017, 109(1). djw186. Doi: 10.1093/jnci/djw186.
[35] ALVAREZ C, SOTO C, CABEZAS S, et al. Panorama of the Intracellular Molecular Concert Orchestrated by Actinoporins, Pore-Forming Toxins from Sea Anemones [J]. Toxins (Basel), 2021, 13(8):567. Doi: 10.3390/toxins13080567.
[36] LABORDE R J, SANCHEZ-FERRAS O, LUZARDO M C, et al. Novel Adjuvant Based on the Pore-Forming Protein Sticholysin II Encapsulated into Liposomes Effectively Enhances the Antigen-Specific CTL-Mediated Immune Response [J]. J Immunol, 2017, 198(7):2772-2784.
[37] CRUZ-LEAL Y, GRUBAUGH D, NOGUEIRA C V, et al. The Vacuolar Pathway in Macrophages Plays a Major Role in Antigen Cross-Presentation Induced by the Pore-Forming Protein Sticholysin Ⅱ Encapsulated Into Liposomes [J]. Front Immunol, 2018, 9(5):2473. Doi: 10.3389/fimmu.2018.02473.
[38] KONDRASHOV O V, GALIMZYANOV T R, PAVLOV K V, et al. Membrane Elastic Deformations Modulate Gramicidin A Transbilayer Dimerization and Lateral Clustering [J]. Biophys J, 2018, 115(3):478-493.
[39] ROUX B. Computational studies of the gramicidin channel [J]. Acc Chem Res, 2002, 35(6):366-375.
[40] ZHANG M, ZHOU X, WANG B, et al. Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma [J]. J Controlled Release, 2013, 168(3):251-261.
[41] GHATAK S, LI J, CHAN Y C, et al. AntihypoxamiR functionalized gramicidin lipid nanoparticles rescue against ischemic memory improving cutaneous wound healing [J]. Nanomedicine, 2016, 12(7):1827-1831.
[42] BENZ R, POPOFF M R. Clostridium perfringens Enterotoxin:The Toxin Forms Highly Cation-Selective Channels in Lipid Bilayers [J]. Toxins (Basel), 2018, 10(9). 2018, 10(9):341. Doi: 10.3390/toxins10090341.
[43] KITADOKORO K, NISHIMURA K, KAMITANI S, et al. Crystal structure of Clostridium perfringens enterotoxin displays features of beta-pore-forming toxins [J]. J Biol Chem, 2011, 286(22):19549-19555.
[44] SAITOH Y, SUZUKI H, TANI K, et al. Tight junctions. Structural insight into tight junction disassembly by Clostridium perfringens enterotoxin [J]. Science, 2015, 347(6223):775-778.
[45] BEIER L S, PIONTEK J, PIONTEK A, et al. Claudin-Targeted Suicide Gene Therapy for Claudin-Overexpressing Tumor Cells by Using Modified Clostridium perfringens Enterotoxin (CPE) [J]. Methods Mol Biol, 2022, 2521(23): 173-188.
[46] BLACK J D, LOPEZ S, COCCO E, et al. Clostridium perfringens enterotoxin (CPE) and CPE-binding domain (c-CPE) for the detection and treatment of gynecologic cancers [J]. Toxins (Basel), 2015, 7(4):1116-1125.
[47] BECKER A, LESKAU M, SCHLINGMANN-MOLINA B L, et al. Functionalization of gold-nanoparticles by the Clostridium perfringens enterotoxin C-terminus for tumor cell ablation using the gold nanoparticle-mediated laser perforation technique [J]. Sci Rep, 2018, 8(1):14963. Doi: 10.1038/s41598-018-37180-8.
[48] BECKER A, LEHRICH T, KALIES S, et al. Parameters for Optoperforation-Induced Killing of Cancer Cells Using Gold Nanoparticles Functionalized With the C-terminal Fragment of Clostridium Perfringens Enterotoxin [J]. Int J Mol Sci, 2019, 20(17):4248. Doi: 10.3390/ijms20174248.
[49] ALNAJJAR S, NOLTE I, BECKER A, et al. Ablation of Red Stable Transfected Claudin Expressing Canine Prostate Adenocarcinoma and Transitional Cell Carcinoma Cell Lines by C-CPE Gold-Nanoparticle-Mediated Laser Intervention [J]. Int J Mol Sci, 2021, 22(22):12289. Doi: 10.3390/ijms222212289.
[50] LANDERS K A, SAMARATUNGA H, TENG L, et al. Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer [J]. Br J Cancer, 2008, 99(3):491-501.
[51] MARTIN D T, LEE J S, LIU Q, et al. Targeting prostate cancer with Clostridium perfringens enterotoxin functionalized nanoparticles co-encapsulating imaging cargo enhances magnetic resonance imaging specificity [J]. Nanomedicine, 2022, 40(3):102477. Doi: 10.1016/j.nano.2021.102477.
[52] SHIM M K, NA J, CHO I K, et al. Targeting of claudin-4 by Clostridium perfringens enterotoxin-conjugated polysialic acid nanoparticles for pancreatic cancer therapy [J]. J Controlled Release, 2021, 331(10):434-442.
[53] SHIM G, KIM M G, JIN H, et al. Claudin 4-targeted nanographene phototherapy using a Clostridium perfringens enterotoxin peptide-photosensitizer conjugate [J]. Acta Pharmacol Sin(中国药理学报), 2017, 38(6):954-962.
[54] JAFARI M, MEHRNEJAD F, AGHDAMI R, et al. Identification of the Crucial Residues in the Early Insertion of Pardaxin into Different Phospholipid Bilayers [J]. J Chem Inf Model, 2017, 57(4):929-941.
[55] TING C H, HUANG H N, HUANG T C, et al. The mechanisms by which pardaxin, a natural cationic antimicrobial peptide, targets the endoplasmic reticulum and induces c-FOS [J]. Biomaterials, 2014, 35(11):3627-3640.
[56] CHEN L, SHEN X, H Y. Research progress of endoplasmic reticulum targeting drug delivery system for anti-tumor immunotherapy [J]. Acta Pharm Sin (药学学报), 2022, 57(1):76-84.
[57] YUAN X, QN B, YIN H, et al. Virus-like Nonvirus Cationic Liposome for Efficient Gene Delivery via Endoplasmic Reticulum Pathway [J]. Acs Cent Sci, 2020, 6(2):174-188.
[58] QIN B, YUAN X, JIANG M, et al. Targeting DNA to the endoplasmic reticulum efficiently enhances gene delivery and therapy [J]. Nanoscale, 2020, 12(35):18249-18262.
[59] QIN B, JIANG M, LI X, et al. Oxygen nanocarrier broke the hypoxia trap of solid tumors and rescued transfection efficiency for gene therapy [J]. J Nanobiotechnol, 2021, 19(1):427. Doi: 10.1186/s12951-021-01144-4.
[60] SHI Y, ZHU C, LIU Y, et al. A Vaccination with Boosted Cross Presentation by ER-Targeted Antigen Delivery for Anti-Tumor Immunotherapy [J]. Adv Healthc Mater, 2021, 10(8):e2001934.
[61] LI W, YANG J, LUO L, et al. Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death [J]. Nat Commun, 2019, 10(1):3349. Doi: 10.1038/s41467-019-11269-8.
[62] TOSTESON M T, TOSTESON D C. The sting. Melittin forms channels in lipid bilayers [J]. Biophys J, 1981, 36(1):109-116.
[63] YU X, DAI Y, ZHAO Y, et al. Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response [J]. Nat Commun, 2020, 11:1-14.
[64] ALHAKAMY N A, BADR-ELDIN S M, ALHARBI W S, et al. Development of an Icariin-Loaded Bilosome-Melittin Formulation with Improved Anticancer Activity against Cancerous Pancreatic Cells [J]. Pharmaceuticals (Basel), 2021, 14(12):1309. Doi: 10.1038/s41467-020-14906-9.
[65] MAO J, LIU S, AI M, et al. A novel melittin nano-liposome exerted excellent anti-hepatocellular carcinoma efficacy with better biological safety [J]. J Hematol Oncol, 2022, 15(1): 130. Doi: 10.1186/s13045-022-01277-5.
[66] LI Y, RUAN S, WANG Z, et al. Hyaluronic Acid Coating Reduces the Leakage of Melittin Encapsulated in Liposomes and Increases Targeted Delivery to Melanoma Cells [J]. Pharmaceutics, 2021, 13(8):1235. Doi: 10.3390/pharmaceutics13081235.
[67] BEI C, BINDU T, REMANT K C, et al. Dual secured nano-melittin for the safe and effective eradication of cancer cells [J]. J Mater Chem B, 2015, 3(1):25-29.
[68] CHENG B, XU P. Redox-Sensitive Nanocomplex for Targeted Delivery of Melittin [J]. Toxins (Basel), 2020, 12(9):582. Doi: 10.3390/toxins12090582.
[69] QI J, CHEN Y, XUE T, et al. Graphene oxide-based magnetic nanocomposites for the delivery of melittin to cervical cancer HeLa cells [J]. Nanotechnology, 2020, 31(6):065102. Doi: 10.1088/1361-6528/ab5084.
[70] YAZDIAN-ROBATI R, ARAB A, RAMEZANI M, et al. Smart aptamer-modified calcium carbonate nanoparticles for controlled release and targeted delivery of epirubicin and melittin into cancer cells in vitro and in vivo [J]. Drug Dev Ind Pharm, 2019, 45(4):603-610.
[71] YE R, ZHENG Y, CHEN Y, et al. Stable loading and delivery of melittin with lipid-coated polymeric nanoparticles for effective tumor therapy with negligible systemic toxicity [J]. ACS Appl Mater Interfaces, 2021, 13(47):55902-55912.
[72] RAVEENDRAN R, CHEN F, KENT B, et al. Estrone-decorated polyion complex micelles for targeted melittin delivery to hormone-responsive breast cancer cells [J]. Biomacromolecules, 2020, 21(3):1222-1233.
[73] SOMAN N R, LANZA G M, HEUSER J M, et al. Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides [J]. Nano Lett, 2008, 8(4):1131-1136.
[74] PORNPATTANANANGKUL D, ZHANG L, OLSON S, et al. Bacterial toxin-triggered drug release from gold nanoparticle-stabilized liposomes for the treatment of bacterial infection [J]. J Am Chem Soc, 2011, 133(11):4132-4139.
[75] ZHANG S, LU X, WANG B, et al. A soft anti-virulence liposome realizing the explosive release of antibiotics at an infectious site to improve antimicrobial therapy [J]. J Mater Chem B, 2021, 9(1):147-158.